Navigation Links
GenWay Biotech Appoints New Vice President Custom Laboratory Services
Date:5/8/2013

SAN DIEGO, May 8, 2013 /PRNewswire-iReach/ -- GenWay Biotech today announced the appointment of Michael Dale as the Company's new Vice President of Custom Laboratory Services. In this role, Mr. Dale will be responsible for providing leadership for GenWay Biotech Custom Services operations and business development initiatives.

"As a key member of the GenWay Biotech senior management team, Mr. Dale brings a wealth of experience and talent to his new role," commented Thomas Silberg , President and CEO of GenWay Biotech. "We look forward to Mr. Dale's leadership and insights to further improve our processes and programs as we endeavor to always provide the utmost quality for our customers."

Mr. Dale brings over thirty years of experience in the biotech industry with a reputation as a resourceful, hands-on leader with proven ability to identify and realize potential in markets, organizations, and people. His experience and knowledge working with limited resources and managing lean operations has enabled the success of several biotech and biomedical start-ups and small to mid-size organizations. Mr. Dale has held executive positions at organizations such as HTI Bio-Products, HTI Bio-Services, Vet-Stem, and Strategic BioSolutions. He holds a Bachelor degree in Business Administration from the Christian Heritage College.

"I am excited to leverage my previous years of experience in custom antibody and contract laboratory at Genway Biotech," stated Michael Dale . "For over 25 years, Genway Biotech has gained an outstanding reputation for providing quality products and services to thousands of diagnostic, pharmaceutical and academia customers. I am privileged to be part of this experienced team, and have the opportunity to help further develop the capabilities, processes and rising stature of the Company.

About GenWay Biotech, Inc.

Since 1998, GenWay Biotech has provided the diagnostic and research communities with thousands of specialty reagents and assays with unmatched quality workmanship at competitive prices. The company is recognized as a trusted out-sourcing partner throughout the world. The Company is comprised of three divisions including the catalog products and custom services divisions focused on protein and antibody solutions, and the FirstMark division focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay's headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information, please visit GenWayBio.com.


Media Contact:

Robert Gans GenWay Biotech, 858-458-0866, rgans@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications
3. Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
4. Frost & Sullivan: Pharma and Biotech Industries Headed Toward an Era of Reduced Profit Margins
5. XBiotech to Present at UBS Global Healthcare Conference
6. TriMix Laboratories Announces New TriMix-gel Partnership with KRS Global Biotechnology
7. Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"
8. Biotech industry has "implementation gap" around demonstrating the value of products under development
9. George Rosenkranz to Receive 2013 Biotechnology Heritage Award
10. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
11. Prodigy Diabetes Care and OK Biotech Align Ownership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... 18, 2017 Viverae ® , a leader ... integration of IBM ® Watson Campaign Automation, implementing ... communications for a personalized experience. Through digital engagement, the ... health in real time. The enhanced experience drives engagement ... members, wherever they are in their journey to health. ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 2017 , ... Journal of Oral Implantology – Tooth loss is ... dental health, including complications with speech, eating, and overcompensation of mouth due to the ... teeth. As the number of tooth replacements increase, it is imperative to design an ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... Gainesville, FL (PRWEB) , ... April 26, 2017 ... ... health and human performance, is proud to announce that it has received 510(k) ... cutting-edge technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
Breaking Medicine News(10 mins):